Alto Neuroscience

📍 Mountain View, United States🗓 Founded 2019👥 77 employees💰 Last funded Apr 2022
Biotechnology🌐 altoneuroscience.com
Website LinkedIn
Alto Neuroscience is redefining psychiatry by leveraging individuals neurobiology to develop personalized and highly effective medicines, helping patients get better faster. ​ Altos Precision Psychiatry Platform™ measures biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to match patients with the treatment they are most likely to respond to. Our approach matches the right patient with the right Alto drug based on AI-derived brain biomarkers, redefining psychiatry at a time when the world needs it most.
7
Total investors
5
Early stage
2
Mid stage
0
Late stage
2019
Founded

Investors

7 investors
All
Early stage
Mid stage
Late stage
Investor geography5 countries
United States
3
Turkey
1
Switzerland
1
United Kingdom
1
Cameroon
1
Investor activity2019–2022 · investors recorded per year
20191202012021320222
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Alto Neuroscience?
Alto Neuroscience has 7 investors on record on gritt.io, including 5 early-stage backers, 2 mid-stage.
When did Alto Neuroscience last raise funding?
The most recent investment in Alto Neuroscience recorded on gritt.io was in April 2022.
When was Alto Neuroscience founded?
Alto Neuroscience was founded in 2019.
What industry is Alto Neuroscience in?
Alto Neuroscience operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Alto Neuroscience based?
Alto Neuroscience is headquartered in Mountain View, United States.